Please assess the completion status of the following clinical trial:

Trial Title: BiRd vs. Rd as Initial Therapy in Multiple Myeloma

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Subject must voluntarily sign and understand written informed consent.~* Subject is at least 65 years old at the time of signing the consent form.~* Subject has histologically confirmed multiple myeloma that has never before been treated~* Subject has no prior anti-myeloma treatment therapy within 14 days prior to initiation of study treatment except for corticosteroids with a maximum allowed dosage equivalent to three pulses of dexamethasone (40mg daily for 4 days equals one pulse). Patients may have received prior adjuvant antiresorptive therapy (i.e., pamidronate or zoledronic acid) as routine care, or radiation therapy as palliation for pain and/or spinal cord compression.~* Subject has measurable disease as defined by \> 0.5 g/dL serum monoclonal protein, \>10 mg/dL involved serum free light chain (either kappa or lambda) provided that the serum free light chain ratio is abnormal, \>0.2 g/24 hrs urinary M-protein excretion, and/or measurable plasmacytoma(s) of at least 1cm in greatest dimension as measured by either CT scanning or MRI.~* Subject has a Karnofsky performance status ≥60% (\>50% if due to bony involvement of myeloma (see Appendix IV).~* Subject is able to take prophylactic anticoagulation as detailed in section 9.1 (patients intolerant to aspirin may use warfarin or low molecular weight heparin).~* Subject is registered into the mandatory RevAssist® program, and is willing and able to comply with the requirements of RevAssist® program.~* If subject is a female of childbearing potential (FCBP),† she must have a negative serum or urine pregnancy test with a sensitivity of at least 25 mIU/mL within 10 - 14 days prior to and again within 24 hours of prescribing lenalidomide~* Subject has a life expectancy ≥ 3 months~* Subjects must meet the following laboratory parameters:~  * Absolute neutrophil count (ANC) ≥750 cells/mm3 (1.0 x 109/L)~ * Hemoglobin ≥ 7 g/dL~ * Platelet count ≥ 30,000/mm3 (75 x 109/L)~ * Serum SGOT/AST \<3.0 x upper limits of normal (ULN)~ * Serum SGPT/ALT \<3.0 x upper limits of normal (ULN)~ * Serum total bilirubin \<2.0 mg/dL (34 µmol/L)~ * Creatinine clearance ≥ 45 cc/min~Exclusion Criteria:~* Subject has immeasurable MM (no measurable monoclonal protein, free light chains in blood or urine, or measureable plasmacytoma on radiologic scanning).~* Subject has a prior history of other malignancies unless disease free for ≥ 5 years, except for basal cell or squamous cell carcinoma of the skin, carcinoma in situ of the cervix or breast, or localized prostate cancer with Gleason score \< 7 with stable prostate specific antigen (PSA) levels.~* Subject has had myocardial infarction within 6 months prior to enrollment , or NYHA(New York Hospital Association) Class III or IV heart failure (see APPENDIX VI), Ejection Fraction \< 35%, uncontrolled angina, severe uncontrolled ventricular arrhythmias, electrocardiographic evidence of acute ischemia or active conduction system abnormalities.~* Female subject who is pregnant or lactating.~* Subject has known HIV infection~* Subject has known active hepatitis B or hepatitis C infection.~* Subject has active viral or bacterial infections or any coexisting medical problem that would significantly increase the risks of this treatment program.~* Subject is unable to reliably take oral medications~* Subject has known hypersensitivity to dexamethasone, clarithromycin, lenalidomide, or thalidomide~* Subject has a history of thromboembolic event within the past 4 weeks prior to enrollment.~* Subject has any clinically significant medical or psychiatric disease or condition that, in the Investigator's opinion, may interfere with protocol adherence or a subject's ability to give informed consent.~* Subject has previously been treated for multiple myeloma

- Gender: ALL
- Minimum Age: 65 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- BiRD treatment regimen (Type: EXPERIMENTAL): Subjects on the BiRD arm will receive clarithromycin, lenalidomide, and dexamethasone in 28-day cycles.
- Rd treatment regimen (Type: ACTIVE_COMPARATOR): Subjects on the Rd arm will receive lenalidomide and dexamethasone in 28-day cycles.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues